<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Progression of cardiac <z:hpo ids='HP_0002459'>autonomic dysfunction</z:hpo> (CADF) in relation to severity of <z:e sem="disease" ids="C0271686" disease_type="Disease or Syndrome" abbrv="">diabetic autonomic neuropathy</z:e> is well documented </plain></SENT>
<SENT sid="1" pm="."><plain>But its progression while coexisting with somatic <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> (PNP) and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) is less described </plain></SENT>
<SENT sid="2" pm="."><plain>We monitored CADF over a period of one year in relation to PNP and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Cardiac autonomic function was assessed in 104 type 2 diabetics </plain></SENT>
<SENT sid="4" pm="."><plain>Based on complications study subjects were divided into four subgroups: Group A (No complications); Group B (with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>); Group C (with PNP); Group D (with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> and PNP) </plain></SENT>
<SENT sid="5" pm="."><plain>The parameters measured were: Expiratory:Inspiratory ratio (E:I ratio) and standard deviation of <z:hpo ids='HP_0000001'>all</z:hpo> the N-N intervals (SDNN) </plain></SENT>
<SENT sid="6" pm="."><plain>These parameters were measured at the baseline and at follow-up </plain></SENT>
<SENT sid="7" pm="."><plain>Data analysis was done by employing suitable statistical tests </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: In Group B: SDNN declined (p&lt;0.001); E:I ratio did not change </plain></SENT>
<SENT sid="9" pm="."><plain>In Group C: E:I ratio declined (p&lt;0.01); SDNN did not change </plain></SENT>
<SENT sid="10" pm="."><plain>In Group D: SDNN and E:I ratio declined significantly (p&lt;0.001) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: CADF coexisting with PNP and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> deteriorates with time </plain></SENT>
<SENT sid="12" pm="."><plain>E:I ratio and SDNN are suitable markers in monitoring CADF coexisting with PNP and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> respectively in type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
</text></document>